Abstract
Protein level of Histo-Blood Group ABO System Transferase (ABO) has been reported to be associated with cardiometabolic diseases. But its effect on pregnancy related outcomes was still unclear. Here we conducted a two-sample Mendelian randomization study to ascertain the putative causal roles of protein levels of ABO in pregnancy related outcomes. Cis-acting protein quantitative trait loci (pQTLs) robustly associated with protein level of ABO (P < 5x10-8) were used as instruments to proxy the ABO level (N = 35,559, data from deCODE), with two additional pQTL datasets from Fenland (N = 10,708) and INTERVAL (N = 3,301) used as validation exposures. Ten pregnancy related diseases and complications were selected as outcomes. We observed that a higher protein level of ABO showed a putative causal effect on venous complications and haemorrhoids in pregnancy (OR = 1.207, 95%CI = 1.107-1.316, colocalization probability = 91.3%), which was validated by using pQTLs from Fenland and INTERVAL. The Mendelian randomization results further showed effects of the ABO protein on gestational hypertension (OR = 0.974, 95%CI = 0.953-0.995), despite insignificance after multiple testing correction and little colocalization evidence. Sensitivity analyses, including proteome-wide Mendelian randomization of the cis-acting ABO pQTLs, showed little evidence of horizontal pleiotropy. Correctively, our study prioritised ABO as a putative causal protein for venous complications and haemorrhoids in pregnancy. Future epidemiology and clinical studies are needed to investigate whether ABO can be considered as a drug target to prevent adverse pregnancy outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by grants from the National Key Research and Development Program of China (2022YFC2505203). Y. B. is supported by the National Natural Science Foundation of China (82088102, 81970728 and 81941017) and the Shanghai Municipal Education Commission_Gaofeng Clinical Medicine Grant Support (20161307 and 20152508 Round 2). Y. B. is a member of the Innovative Research Team of High-level Local Universities in Shanghai.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: www.ncbi.nlm.nih.gov/pubmed/35859178; www.ncbi.nlm.nih.gov/pubmed/34648354; www.ncbi.nlm.nih.gov/pubmed/29875488; r9.finngen.fi; gwas.mrcieu.ac.uk;
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
format revised; author affiliations updated
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
